Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery

NCT ID: NCT04060771

Last Updated: 2019-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-01

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, double-blind study comparing Palonosetron and Dexamethasone in the prophylaxis of Post-Operative Nausea and Vomiting in children submitted to Strabismus surgery ABSTRACT Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.

Objective: The study aims to compare the incidence of PONV after intravenous administration of palonosetron or dexamethasone in pediatric patients undergoing elective strabismus surgery under general anesthesia.

Materials and Methods: This prospective, double-blind study consist of 80 patients of both genders, classified as ASA grade I and II, ranging in age from 2 to 15 years, scheduled for elective strabismus surgery at Hospital Universitário Antonio Pedro(HUAP), after consent by their parents. Patients will be randomized into two groups of 40 patients each. Group P will receive intravenous dose of palonosetron (1 mg.kg-1), and Group D will receive dexamethasone (0.2 mg.kg-1) after induction of anesthesia. Pacients will be observed for 6 hours before discharge and post-discharge symptoms will be assessed through telephone survey after 24 and 48 hours. At the end of the study, results will be compiled and statistical analysis will be done by using Mann-Whitney test, Chi-squared test and Fisher test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia Strabismus PONV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will be divided between two groups, Group P will receive single dose of palonosetron whereas Group D will receive a single dose of dexamethasone during general anesthesia.
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators
Double-blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group P

During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.

Group Type EXPERIMENTAL

Palonosetron

Intervention Type DRUG

prophylaxis of postoperative nausea and vomiting

Group D

During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

prophylaxis of postoperative nausea and vomiting

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Palonosetron

prophylaxis of postoperative nausea and vomiting

Intervention Type DRUG

Dexamethasone

prophylaxis of postoperative nausea and vomiting

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prophylactic Prophylactic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children undergoing elective strabismus surgery
* Physical state according to an American Society of Anesthesiologists (ASA) I and II

Exclusion Criteria

* Children nor involved in surgery
* Participation in another study in the last month
* Previous history of PONV
* Occurrence of episodes of nausea or vomiting in the last 24 hours before surgery
* Chronic use of corticosteroids
* Previous history of motion sickness
* Use of psychoactive drugs or any other medicine with an antiemetic effect;
* Known hypersensitivity to any study medication
* Severe diseases in organs such as kidney, liver, lung, heart, brain and bone marrow
Minimum Eligible Age

2 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidade Federal Fluminense

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alexandra Rezende Assad, PhD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Júlio CA Moreira, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitário Antonio Pedro

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitário Antonio Pedro

Niterói, Rio de Janeiro, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexandra R Assad, MD, MSc, PhD

Role: CONTACT

5521999859746

Ismar L Cavalcanti, MD, MSc, PhD

Role: CONTACT

5521999822993

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Strabismus surgery

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PALONOSETRON X FOSAPREPITANT IN PONV
NCT03586817 UNKNOWN PHASE4